Skip to main content
Premium Trial:

Request an Annual Quote

Multiple Myeloma Study Suggests Circulating DNA Test Complements Bone Marrow Testing

NEW YORK (GenomeWeb) – There is new evidence that circulating tumor DNA can offer a window into mutations present in multiple myeloma (MM) tumors that could potentially offset the need for at least some of the bone marrow testing procedures patients need to endure.

In a study appearing online today in Nature Communications, a Canadian team outlined their method for detecting multiple myeloma (MM) mutations with the help of circulating tumor DNA sequencing. The approach, dubbed Liquid Biopsy Sequencing (LB-Seq), appeared to uncover the majority of MM mutations, suggesting it could serve as an avenue for detecting and characterizing MMs in a manner that is complementary to more invasive bone marrow aspiration-based testing.

The LB-Seq approach "can potentially replace medically unnecessary [bone marrow] sampling and provide an alternative non-invasive test for longitudinal genetic monitoring of MM patients receiving targeted therapy," co-corresponding authors Trevor Pugh and Suzanne Trudel, researchers affiliated with the Princess Margaret Cancer Centre and University of Toronto, and their colleagues wrote.

They explained that such a method is attractive because MM tumor testing typically involves a bone marrow aspiration process that "may be difficult, painful, and associated with significant patient anxiety as well as rare but significant complications including bleeding and infection."

The general LB-Seq strategy uses hybrid capture to grab sequences of interest out of a collection of circulating, cell-free DNA in the blood so that they can be profiled by deep Illumina sequencing. That sequence data is subsequently untangled using a variant filtering algorithm designed to find mutated sequences stemming from the MM tumor — even when these alterations represent a relatively small proportion of the cell-free DNA in the blood.

For their analysis, the researchers focused on protein-coding exon sequences for a handful of cancer-related genes: KRAS, NRAS, BRAF, EGFR, and PIK3CA. Using 64 ctDNA samples obtained from blood for 11 individuals with newly diagnosed MM and 42 individuals with a relapsed form of the disease, for example, they detected apparent actionable mutations in 34 individuals.

When the team compared the mutations detected with LB-Seq by those identified with bone marrow testing, meanwhile, they found that the circulating, cell-free DNA sequencing-based approach successfully picked up all but two somatic mutations present in four-dozen matched bone marrow samples, while pointing to four potential mutations not described from bone marrow-based sequences.

Based on their findings so far, the study's authors concluded that the LB-Seq strategy "can accurately detect 96 percent of mutations identified by genetic profiling of matched [bone marrow]-derived tumor DNA with more than 98 percent specificity, similar sub-clonal hierarchies, and good concordance between serial plasma samples."

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.